The Medical Science Liaison will be responsible for field responsibilities and KOL relationships in the North Central region. The North Central region encompasses Michigan, Indiana and Northern Kentucky.  Only candidates that currently reside in the territory will be considered.

Summary of Key Responsibilities

• Partner closely with investigators and internal stakeholders to drive patient accrual.
• Identify key opinion leaders and cultivate a network of experts for key Alnylam disease areas.
• Develop, maintain, and execute US KOL and US Institution plans within respective geography.
• Conduct and implement a comprehensive disease awareness tactical plan within the respective geography.
• Collaborate with health care professionals to identify opportunities for the development of algorithms and guidelines to facilitate early diagnosis
• Provide in-depth drug mechanism of action and emerging clinical information to health care providers in the respective geography.
• Serve as a liaison to health care professionals and professional organizations and disease state advocacy groups.  Support the efforts of patient support groups and educational foundations.
• Provide medical and scientific input into the planning and execution of advisory boards and work with experts to review speaker presentations and provide additional medical background where requested.
• Contribute to Alnylam's achievement of Company objectives for pre-approved products.
• Provide educational meeting support at scientific congresses.
• Coordinate required medical, legal, and regulatory review and approval of all field documents for distribution or presentation.
• Require 60-70% travel.
• Must live in territory

Qualifications

• PhD, PharmD, DNP or MD with 4+ years of industry experience in MSL role
• Proven clinical background to enable engagement of Health Care Professionals in a scientifically meaningful exchange.
• Prior experience in rare disease strongly preferred.
• Experience in clinical research, patient recruitment, and investigator-sponsored trials.
• Experience in medical education and KOL management.
• Effective communication of evidence based scientific information.
• Ability to work collaboratively and cross-functionally.
• Capable of managing shifting priorities in a rapidly changing and environment
• Decision-making and accountability.
• Clear alignment with Alnylam Core Values

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.